Prediagnostic Serum Biomarkers as Early Detection Tools for Pancreatic Cancer in a Large Prospective Cohort Study

Brian M. Nolen¹, Randall E. Brand², Denise Prosser¹, Liudmila Velikokhatnaya¹, Peter J. Allen³, Herbert J. Zeh¹,⁴, William E. Grizzle⁵, Aleksey Lomakin⁶, Anna E. Lokshina¹,⁷,⁸,⁹*

¹University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States of America, ²Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh and University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States of America, ³Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America, ⁴Department of Surgery, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America, ⁵Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America, ⁶Department of Physics, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America, ⁷Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America, ⁸Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America, ⁹Department of Ob/Gyn, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

Abstract

Background: The clinical management of pancreatic cancer is severely hampered by the absence of effective screening tools.

Methods: Sixty-seven biomarkers were evaluated in prediagnostic sera obtained from cases of pancreatic cancer enrolled in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO).

Results: The panel of CA 19-9, OPN, and OPG, identified in a prior retrospective study, was not effective. CA 19-9, CEA, NSE, bHCG, CEACAM1 and PRL were significantly altered in sera obtained from cases greater than 1 year prior to diagnosis. Levels of CA 19-9, CA 12S, CEA, PRL, and IL-8 were negatively associated with time to diagnosis. A training/validation study using alternate halves of the PLCO set failed to identify a biomarker panel with significantly improved performance over CA 19-9 alone. When the entire PLCO set was used for training at a specificity (SP) of 95%, a panel of CA 19-9, CEA, and Cyfra 21-1 provided significantly elevated sensitivity (SN) levels of 32.4% and 29.7% in samples collected <1 year and >1 year prior to diagnosis, respectively, compared to SN levels of 25.7% and 17.2% for CA 19-9 alone.

Conclusions: Most biomarkers identified in previously conducted case/control studies are ineffective in prediagnostic samples, however several biomarkers were identified as significantly altered up to 35 months prior to diagnosis. Two newly derived biomarker combinations offered advantage over CA 19-9 alone in terms of SN, particularly in samples collected >1 year prior to diagnosis. However, the efficacy of biomarker-based tools remains limited at present. Several biomarkers demonstrated significant velocity related to time to diagnosis, an observation which may offer considerable potential for enhancements in early detection.

Citation: Nolen BM, Brand RE, Prosser D, Velikokhatnaya L, Allen PJ, et al. (2014) Prediagnostic Serum Biomarkers as Early Detection Tools for Pancreatic Cancer in a Large Prospective Cohort Study. PLoS ONE 9(4): e94928. doi:10.1371/journal.pone.0094928

Editor: Francisco X. Real, Centro Nacional de Investigaciones Oncológicas (CNIO), Spain

Received October 28, 2013; Accepted March 21, 2014; Published April 18, 2014

Copyright: © 2014 Nolen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by funding provided in the following NIH awards: 2RO1CA108990, U01CA117452, and SP3O CA047904 23. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: lokshina@pitt.edu

Introduction

Pancreatic cancer is the fourth leading cause of cancer death in the United States. In 2013, an estimated 43,924 people will be diagnosed with pancreatic cancer and 37,390 will perish from the disease [1]. The high lethality associated with pancreatic ductal adenocarcinomas (PDAC), which constitute 85–90% of pancreatic cancer diagnoses, can be largely attributed to the presence of advanced disease at the time of diagnosis. PDAC is characterized by clinical manifestations which present late in the natural history of the disease at a stage when metastasis is a common finding, leading to a median survival of 6 months and an overall 5-year survival of <5% [2]. Outcomes are significantly improved in the minority of patients who present with small, surgically-resectable cancers for which there is a realistic chance of cure and a 5-year survival rate of 20–30% [3]. Considerable effort is currently devoted to the discovery and development of blood-based biomarkers capable of detecting PDAC at early, preclinical stages in appropriately targeted demographic groups.

Population-based screening for pancreatic cancer among asymptomatic individuals remains impractical based on the rarity of the disease and the lack of diagnostic tests with adequate accuracy. An effective screening test in this setting would require
not only a high sensitivity (SN) for pancreatic cancer but also a level of specificity (SP) exceeding 99% in order to maintain an acceptably low level of false positive results. Screening programs targeting high-risk individuals are likely to be effective at more attainable performance standards due to the enrichment of PDAC prevalence within these populations. The mucin-associated
sialylated Lewis (a) antigen CA 19-9 is a biomarker of PDAC shown to be ineffective as a standalone screening test. CA 19-9 has demonstrated modest effectiveness when applied as a diagnostic tool in symptomatic individuals on an outpatient basis with a median SN of 79% (range 70–90%) and median SP of 82% (range 68–91%), however it is not useful in the mass screening of asymptomatic subjects [4]. The principal limitations of CA 19-9 include its frequent elevation associated with pancreatitis and obstructive jaundice, conditions which frequently co-occur with pancreatic cancer and a variety of benign conditions.

The use of multiplex biomarker combinations has provided some advancement in the search for effective diagnostic tests for PDAC. Recent findings have generated interest in two potential biomarkers, osteopontin (OPN) and TIMP-1, in the early detection of pancreatic cancer [5–7]. TIMP-1 was also included in a three-biomarker panel along with CA 19-9 and carcinoembryonic antigen (CEA), which provided a SN/SP of 76/90 for the classification of pancreatic cancer from benign pancreatic disease [8]. In the same study, a panel comprised of CA 19-9, ICAM-1 and osteoprotegerin (OPG) provided a SN/SP of 88/90 for the discrimination of pancreatic cancer from healthy controls. Most recently, the combination of OPN, TIMP-1 and CA 19-9 was found to be effective in the discrimination of patients with pancreatic cancer from a group of healthy controls and patients diagnosed with pancreatitis [9]. The major limitation associated with these findings is the use of serum samples obtained near or after the time of PDAC diagnosis. Several groups have attempted the identification of PDAC biomarkers in pre-diagnostic samples. In a study by Faca et al., a panel of seven proteins with or without the addition of CA 19-9, selected based on findings in a mouse model, was able to discriminate human pancreatic cancer cases from matched controls in a small group of pre-symptomatic and pre-diagnostic subject included in the CARET (Carotene and Retinol Efficacy Trial) cohort [10]. Others have utilized larger prospective cohorts to separately implicate C-peptide levels and the IGF-1/IGFBP-3 ratio as markers of pancreatic cancer risk [11,12].

In the current study we investigated the efficacy of a large group of serum biomarkers, including several combinations shown previously to be effective in a retrospective case/control cohort, in pre-diagnostic samples collected from patients diagnosed with PDAC who were enrolled in the large Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO).

### Materials and Methods

#### Ethics statement

All subjects involved in this study were over the age of 18 and provided written informed consent. Since signed informed consent was a criterion for eligibility to participate in the PLCO trial, each Screening Center determined the preliminary eligibility of potential participants and obtained their consent before enrolling them in the study. The Coordinator for each Screening Center was formally responsible for ensuring that informed written consent was obtained from each study participant. In addition, the Institutional Review Board (IRB) at each Screening Center approved the informed consent form(s) and specimen collection procedures. PLCO Screening Centers included the following: University Of Colorado, Georgetown University, Pacific Health Research & Education Institute, Henry Ford Health System, University Of Minnesota, Washington University, University Of Pittsburgh, University Of Utah, Marshfield Clinic Research Foundation, University Of Alabama At Birmingham, UCLA Immunogenetics Center. The current study was approved by the University of Pittsburgh IRB.

#### Selection of cases and controls

The PLCO Cancer Screening Trial is a randomized multicenter trial in the United States, previously described in detail [13], which was aimed at evaluating the impact of early detection procedures for prostate, lung, colorectal, and ovarian cancer on disease-specific mortality. The study recruitment and randomization began in November 1993 and was completed in July 2001. The cohort comprised 152,810 men and women aged 55 to 74 years old at baseline.

Pancreatic cancer cases present among cohort participants were identified by self-report in annual mail-in surveys, state cancer registries, death certificates, physician referrals, and reports from next of kin for deceased individuals. All medical and pathologic records related to pancreatic cancer diagnosis and supporting documentation were obtained and abstracted by trained medical record specialists for cancer confirmation. Incident cases of primary adenocarcinoma of the exocrine pancreas (International Classification of Disease for Oncology, 3rd edition code C250–C259) were included in current study. There were one hundred thirty-five incident cases of pancreatic adenocarcinomas between 1994 and 2006 (follow-up to 11.7 years; median, 5.4 years)

### Table 2. Complete List of Evaluated Biomarkers.

| Category          | Biomarkers                                                                 |
|-------------------|-----------------------------------------------------------------------------|
| Tumor Markers     | ALCAM[20], AFP[21], CA 19-9[22], CA 72-4[23], CA125[24], CEA[25], CEACAM-1[26], CEACAM-6[27], CYFRA 21-1[28], HE4[29] |
| Acute Phase       | Apo CII[30], Apo E[31], Complement C4[31], CRP[32], transthyretin (TTR)[33] |
| Hormones          | FSH[34], GH[34], bHCG[35], prolactin (PRL)[34]                               |
| Growth Factors    | EGR[34], erbB2[34], FGF2[36], HGF[37], IGFBP-3[38], VEGFR1[38], VEGFR2[38], VEGFR3[38], TGFβ[38] |
| Apoptosis         | Fas[39], Fasl[39], clusterin[40]                                           |
| Cytokines/Inflammation | IL-6[41], MIF[34], MPO[34], IL-1R1[42], IL-4[42], IL-6[42], TNFRI[34], TNFRII[34], YKL40[42], MIC-1[59], MIP-4[59], HIF-1α[42] |
| Metastasis        | MMP-3[34], MMP-9[34], TIMP-1[43], TIMP-2[44], TIMP-3[44], TIMP-4[44]        |
| Adhesion          | ICAM-1[10], VCAM-1[34], NCAM[60], Periostin[45]                             |
| Gut Proteins      | Cathepsin D[46], Insulin[47], PTH[34]                                      |
| Neural Factors    | AGR[48], BDNF[49], CNTF[50], NSE[50]                                       |
| Bone metabolic proteins | Osteocalcin (OC)[34], osteoprotegerin (OPG)[34], osteonectin (OSN)[51], osteopontin (OPN)[34], TRAPS[52] |

* - our unpublished observations

http://dx.doi.org/10.1371/journal.pone.0094928.t002
confirmed through medical review. Controls, alive at the time when the index case was diagnosed, were randomly selected from all PLCO participants. Controls were matched to cases at a ratio of 4:1 (controls:cases) based on the distribution of age (±5 years), race, sex, and calendar date of blood draw in 2-month blocks within the case cohort.

Study design

Serum samples were provided by the PLCO administrators to UPCI in a blinded fashion for biomarker analysis (Table 1). According to the PLCO requirements, the analysis was performed in 5 steps as follows.

Step 1. Initial training on a retrospective case/control set. The entire case/control set reported in [8] was used for training to identify optimal biomarker combinations, establish classification rules, and calculate scoring functions using the MMC algorithm (described below). This set consisted of 343 patients diagnosed with PDAC (163 men, 180 women, median age 68, age range 29–92) and 227 healthy controls (88 men, 139 women, median age 56, age range 18–87). The stage distribution for cases was 2.3% stage 1, 20% stage 2, 10% stage 3, 25% stage 4, and 39% unknown.

Step 2. Validation of an initial algorithm in the first, blinded one-half of the PLCO set. The first, blinded one-half of the PLCO set was analyzed for biomarkers included in the optimal combinations identified in Step 1. Two scoring functions determined in Step 1 were applied to this half of the PLCO set in order to assign diagnoses to each subject. These experimental diagnoses were then forwarded to the PLCO administrators for comparison to actual diagnoses and the diagnostic efficacy [SN, SP, area under the ROC curve (AUC)] of each biomarker combination was reported back to UPCI.

Step 3. Training on the first one-half of the PLCO set following unblinding. Once the results of the blinded PLCO training analysis were reported, the case/control status of those samples was unblinded in order to permit further biomarker analyses. This one-half of the set was evaluated for the entire panel of 67 biomarkers and used as a training set for development of improved algorithms.

Step 4. Validation of the results from Step 3 in the second, blinded one-half of the PLCO set. The improved algorithm was applied to the second blinded one-half of the PLCO set and scoring functions and diagnoses (cancer/healthy) were then forwarded to the PLCO. The experimental diagnoses were again compared to the actual diagnoses and the diagnostic efficacy (SN, SP, AUC) of each biomarker combination was reported back to UPCI.

Step 5. Training on the entire PLCO set. The entire PLCO set was unblinded, the full set of 67 candidate biomarkers were measured in all PLCO samples, and the entire dataset was utilized for development of a further optimized algorithm.

Multiplexed Biomarker Analysis

A total of 67 multiplexed bead-based immunoassays targeting specific protein biomarkers were utilized over the course of the current study (Table 2). We previously reported the performance of several biomarker combinations in the discrimination of PDAC cases from healthy control subjects in a large retrospective case/control study [8]. In addition to biomarkers reported to be significantly altered in [8], a number of additional candidate biomarkers were analyzed, including AGRP, BDNF, CNTF, Cathepsin D, NCAM, MIC-1, MIP4, complement C4, clusterin, IGFBP3, periostin, and TTR. Assays targeting CEACAM-1, CEACAM-6, ALCAM, and HIF-1α were developed according to
strict quality control standards by the UPCI Luminex Core Facility [14] and were performed as described previously [15]. Assays targeting TIMPs 1-4 and MMP-3 were obtained from R&D Systems (Minneapolis, MN) and all remaining assays were obtained from EMD Millipore (Billerica, MA). All commercially obtained assays were performed according to manufacturer instructions. The complete biomarker dataset has been deposited with the Early Detection Research Network (EDRN) of the National Cancer Institute (NCI) and can be accessed at https://edrn.jpl.nasa.gov/ecas/data/dataset/urn:edrn:Analysis_of_pancreatic_cancer_biomarkers_in_PLCO_set.

### Univariate and Multivariate Statistical Analysis

For the univariate analysis, biomarker measurements among the case and control groups were evaluated by the Mann-Whitney non-parametric U test. An initial minimum level of significance of \( p \leq 0.05 \) was utilized. The false discovery rate (FDR) was controlled at 5% according to the method of Benjamini and Hochberg[16]. Briefly, the individual \( p \)-values for each biomarker comparison were ranked from most to least significant. The ranked, unadjusted \( p \)-values were then compared to the statistic \( \frac{q}{iq/m} \), where \( i \) is the \( p \)-value rank, \( q \) is the FDR (0.05), and \( m \) is the total number of biomarker comparisons tested. Individual biomarker mean, SN, and AUC values were determined using Graphpad PRISM software (La Jolla, CA).

A Metropolis algorithm with Monte Carlo optimization (MMC) was used for the multivariate analysis of the biomarker results as described previously [17]. Briefly, all biomarker combinations of a predetermined size are examined. A scoring function (SF) is calculated for each biomarker panel as a linear combination of logarithms of biomarker concentrations multiplied by a coefficient for each biomarker assigned by Monte Carlo optimization. The resulting set of SFs for each biomarker combination is then evaluated for classification efficiency using 500 cross-validation. In order to avoid overfitting bias, our analysis was limited to panels consisting of 2, 3, or 4 biomarkers. In the Training analyses (Steps 3 and 5), panels were evaluated based on SN at predetermined SP levels of 95% and the statistical significance of differences in SN was assessed using McNemar’s test for correlated proportions as described in [18]. A value for \( x^2 \) of 3.841 offering a 5% significance level was used as a cutoff point. In the Training and Validation analyses (Steps 2–5), differences in AUC were assessed for significance as described by Hanley and McNeil [19]. Here, a \( Z \) ratio of \( \pm 2 \) was used as a cutoff point for statistical significance.

### Table 4. Performance of Multimarker Combinations in PLCO Training and Validation Sets.

| Step 1. Training Case/Control Set* | SN/SP/AUC |
|-----------------------------------|-----------|
| CA 19-9/OPG                       | 74.8/95.0/0.925 |
| CA 19-9/OPG/OPN                   | 82.4/95.0/0.935 |

| Step 2. Validation on blinded first-half of PLCO set | Complete Set | MTD 1–12 | MTD 12–35 |
|-----------------------------------------------------|--------------|----------|-----------|
| CA 19-9                                             | 23.2/90.2/652 | 20.7/90.2/669 | 25.9/90.2/633 |
| CA 19-9/OPG                                         | 32.1/87.8/570 | 31.0/87.8/614 | 33.3/87.8/523 |
| CA 19-9/OPG/OPN                                     | 30.4/84.7/547 | 37.9/84.7/596 | 22.2/84.7/494 |

| Step 3. Training on unblinded first-half of PLCO set | Complete Set | MTD 1–12 | MTD 12–35 |
|-----------------------------------------------------|--------------|----------|-----------|
| CA 19-9                                             | 17.9/95.0/652 | 17.2/95.0/669 | 18.5/95.0/633 |
| CA 19-9/CEA                                         | 30.4/95.0/665 | 42.3/95.0/749 | 20.0/95.0/555 |

| Step 4. Validation in blinded second-half of PLCO set | Complete Set | MTD 1–12 | MTD 12–35 |
|-----------------------------------------------------|--------------|----------|-----------|
| CA 19-9                                             | 25.3/93.2/656 | 38.1/93.2/695 | 10.8/93.2/616 |
| CA 19-9/CEA                                         | 31.7/94.4/668 | 40.5/94.4/710 | 21.8/94.4/620 |

| Step 5. Training on the entire unblinded PLCO set | Complete Set | MTD 1–12 | MTD 12–35 |
|-----------------------------------------------------|--------------|----------|-----------|
| CA 19-9                                             | 21.8/95.0/656 | 25.7/95.0/680 | 17.2/95.0/626 |
| CA 19-9/CEA                                         | 28.1/95.0/616 | 26.7/95.0/666 | 28.1/95.0/657 |
| CA 19-9/CEA/Cyfra 21-1                              | 30.4/95.0/678 | 32.4/95.0/692 | 29.7/95.0/663 |

*Case/Control set described in [8].

# Statistical significance of differences in SN in comparison with CA 19-9 alone, method described in [18].

SN/SP/AUC – sensitivity/specificity/area under ROC curve.

MTD 1–12 – months to diagnosis 1–12, samples collected <12 months prior to diagnosis.

MTD 12–35 – months to diagnosis 12–35, samples collected 12 to 35 months prior to diagnosis.

doi:10.1371/journal.pone.0094928.0004
Reproducibility of biomarker measurements and MMC scoring

The reproducibility of the biomarker measurements and the MMC algorithm was assessed through the inclusion of 17 duplicate samples embedded within the blinded PLCO set (7 cases/10 controls). Coefficients of variation (CV) were calculated for each duplicate set for each biomarker tested. Diagnoses determined by the MMC algorithm were compared within each duplicate set for consistency.

Biomarker correlations with CA 19-9 levels and associations with time to diagnosis

Correlations between each of the biomarkers included in the current study and CA 19-9 were evaluated in the cases using the Pearson test of correlation with a minimum level of significance of \( p \leq 0.05 \). To assess the association between biomarker concentrations and time to diagnosis, biomarker levels were plotted against time to diagnosis measured in days for the complete set of cases from the PLCO set. Curves were evaluated by linear regression in order to identify those with non-zero slope values with a minimum level of significance of \( p \leq 0.05 \).

Results

Reproducibility

Coefficients of variation (CV) reflecting reproducibility in the measurement of 67 biomarkers, varied from 0% to 18.8% with average CV for each biomarker varying from 1.0% to 7.8% (Table 3 for nine representative biomarkers and data not shown). Diagnoses assigned by the MMC algorithm were consistent among each pair of duplicate samples.

Multimarker panel discovery, training and validation

Step 1. In the retrospective case/control set, the combination of CA 19-9/OPG offered the highest performance of all two biomarker panels with a SN of 74.8% at 95% SP and an AUC value of 0.925, while the combination of CA 19-9, OPG, OPN offered the highest classification power of all 3-biomarker panels with SN = 82.4% at a SP = 95% and AUC = 0.954 (Table 4). None of the possible 4-biomarker panels offered a significant advantage over the CA19-9/OPG/OPN combination (data not shown). Therefore, the CA 19-9/OPG and CA 19-9/OPG/OPN panels were selected for evaluation in the prospective PLCO cohort.

Step 2. Overall, the performance of selected panels was markedly diminished in the pre-diagnostic PLCO samples in comparison to the case/control samples obtained at the time of diagnosis (Table 4). In the complete set as well as in subsets including cases diagnosed within 12 months of sample collection [months to diagnosis (MTD) 1–12 group] and those diagnosed 12–35 months after collection (MTD 12–35 group), both the CA 19-9/OPG and CA 19-9/OPG/OPN biomarker combinations provided statistically similar AUC values, which in turn did not differ significantly from that of CA 19-9 alone.

Step 3. Next, the MMC algorithm was applied to the unblinded one-half of the PLCO set in which a larger pool of 67 candidate biomarkers was measured. All SN values were determined at 95% SP in order to approximate the requirements for high SP in PDAC screening. CA 19-9 alone offered 17.9% SN at 95% SP in the entire set with 17.2% SN in the MTD 1-12 group and 18.3% SN in the MTD 12–35 group. The combination of CA 19-9/CEA performed better than CA 19-9 alone and provided a SN of 30.4% at 95% SP for the entire set and SNs of 42.3% and 20% for the MTD 1-12 and MTD 12–35 groups, respectively. Differences in SN of the CA 19-9/CEA combination vs. CA 19-9 alone reached statistically significant levels when assessed in the entire set and in MTD 1–12 group (Table 4).

Step 4. Two sets of diagnoses for the second, blinded one-half of the PLCO set were forwarded to the PLCO administrators using the following classifiers: CA 19-9 alone and CA 19-9/CEA.

The combination of CA 19-9/CEA provided somewhat elevated levels of SN, SP and AUC over CA 19-9 alone (Table 4), however the observed differences in AUC did not reach statistical significance.

Step 5. Finally, the entire PLCO set was unblinded for training using the complete panel of 67 biomarkers. The MMC algorithm was used to evaluate all possible combinations of 2, 3 and 4 biomarkers in the complete PLCO cohort at a preset SP of 95%. CA 19-9 alone was 21.8% sensitive in the entire set, with 25.7% SN in the MTD 1–12 group and 17.2% SN in the MTD 12–35 group (Table 4). As expected, among all possible 2-biomarker panels, the CA 19-9/CEA combination had the highest diagnostic power with 28.1% SN in the entire set, 26.7% SN in the MTD 1–12 group, and 28.1% in the MTD 12–35 group.
evaluated 3-biomarker combinations, the combination of CA 19-9/CEA/Cyfra 21-1 offered some advantage with an overall SN of 30.4%, a SN of 32.4% in the MTD 1–12 group, and a SN of 29.7% in the MTD 12–35 group, all at 95% SP. The CA 19-9/CEA combination demonstrated higher levels of SN in comparison to CA 19-9 alone in the complete set and the MTD 1–12 set, however neither of these differences were statistically significant. The CA 19-9/CEA panel provided a significantly improved SN over CA 19-9 alone in the MTD 13–35 set. The combination of CA 19-9/CEA/Cyfra 21-1 provided significantly improved SN levels in all three case sets. ROC curves demonstrating the performance of each of the top biomarker panels and CA 19-9 alone are presented in Figure 1.

**Individual biomarker performance.** Upon completion of the current study, a total of 67 biomarkers were evaluated in the full unblinded PLCO set. Among these, eight biomarkers were found to differ significantly among the case and control groups according to the MWU test: CA 19-9, CEA, CA 125, NSE, CEACAM1, IL-8, PRL, and bHCG (Figure 2, Table 5). After controlling for a false discovery rate of 5%, the level of significance was set at $p < 0.03$. Each significantly altered biomarker was observed at higher levels in cases than in controls, with the exception of PRL, which was observed at lower levels in the cases. CA 19-9, CEA, NSE, and bHCG demonstrated differences in both the MTD 1–12 and MTD 12–25 subsets, whereas differences in CA 125 and IL-8 reached statistical significance in only the MTD 1–12 subset. Differences in CEACAM1 and PRL were significant in the 12–35 MTD and 24–35 MTD groups but not in the 1–12 MTD groups.

**Biomarker associations with time to diagnosis and correlations with CA 19-9 levels.** Levels of CA 19-9, CA 125, CEA, PRL, AGRP, and IL-8 demonstrated negative associations with time to diagnosis with linear regression slopes differing significantly from zero (Figure 3). Importantly, CA 19-9, PRL, and AGRP showed slopes significantly differing from zero in samples collected more than 12 months before diagnosis. Additionally, several biomarkers (Cyfra 21-1, TNFR1, ErbB2, CNTF, IL-6R, HIF-1a, TIMP-4 and ALCAM) demonstrated regression slopes which were significant only when analyzed in samples collected more than 12 months before diagnosis, but not in the overall set (Figure 3). Only CA 125 ($r^2 = 0.5361$, $p < 0.0001$) and CEA ($r^2 = 0.6947$, $p < 0.0001$) were observed to be significantly correlated with CA 19-9.

**Discussion**

We report here a systematic analysis of 67 serum protein biomarkers in pre-diagnostic samples collected from patients diagnosed with PDAC in the course of the PLCO study. Published reports and our previous case/control analysis utilizing sera drawn at the time of pancreatic cancer diagnosis yielded a broad and diverse spectrum of biomarker alterations [20–46]. From these results, we concluded that local and systemic responses to tumor progression in advancing and/or symptomatic disease resulted in an extensive milieu of factors detectable in the sera of pancreatic cancer patients. The results of our current study reflect the challenges associated with the detection of early asymptomatic disease in that only a subtile array of 8 biomarker alterations was observed. Our analysis of biomarker level trends across the prediagnostic course of PDAC indicate that CEACAM1 and PRL are the earliest to be detected at significantly altered levels at time points up to 35 months prior to diagnosis. Subsequently, changes in CA 19-9, CEA, NSE, and bHCG are observed that are detectable up to 24 months before diagnosis. Finally, levels of CA

| Table 5. Individual Performance of Significantly Altered Serum Biomarkers. |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| **PDAC vs. Healthy** | **PDAC (ng/ml)** | **Healthy (ng/ml)** | **PDAC vs. Healthy (ng/ml)** | **PDAC (ng/ml)** |
| **PDAC** | **Healthy** | **PDAC** | **Healthy** | **PDAC** | **Healthy** |
| CA 19-9 | 0.173 | 0.155 | 0.44 | 0.215 | 0.656 | 0.577 |
| CEA | 1.199 | 1.52 | 4.8 | 2.790 | 4.6 | 0.577 |
| CA 125 | 3.156 | 1.900 | 4.11 | 5.150 | 4.6 | 0.577 |
| NSE | 209 | 374 | 51.1 | 240 | 60 | 0.577 |
| IL-8 | 2.34 | 4.1 | 9.47 | 2.43 | 7.47 | 0.577 |
| bHCG | 0.230 | 0.218 | 0.518 | 0.218 | 0.518 | 0.577 |
| CEACAM1 | 372 | 154 | 372 | 626 | 118 | 0.577 |
| PRL | 4060 | 144000 | 4060 | 144000 | 0.577 |
| AUC | 0.656 | 0.525 | 0.577 | 0.577 | 0.577 |

Cut-point – minimum (maximum for prolactin) value (ng/ml) for diagnosis as case at 95% specificity. 
SN – sensitivity at 95% specificity. 
AUC – area under ROC curve. 
doi:10.1371/journal.pone.0094928.t005
Figure 2. Prediagnostic distributions of serum biomarker levels. Levels of 67 biomarkers were evaluated in sera obtained from 135 subjects enrolled in the PLCO cancer screening trial who were subsequently diagnosed with pancreatic cancer and 540 matched controls. Circulating levels of biomarkers demonstrating significant differences between cases and healthy controls are presented. Level of significance: * - p<0.03, ** - p<0.01, *** - p<0.001, **** - p<0.0001.

doi:10.1371/journal.pone.0094928.g002

125 and IL-8 are detectably elevated up to 12 months before diagnosis. Importantly, these results demonstrate the limitations of using CA 19-9 as a biomarker for very early or pre-neoplastic disease.

Our results suggest that several circulating PDAC biomarkers which have been identified in case/control studies, including MIC-1, TIMP-1, ICAM1, HE4, OPG, MUC1, MMP9, SAA, and others [10,34,47], may not be useful for prediagnostic risk assessment. However, as a number of biomarkers differentially expressed in pre-diagnostic samples in the current study (CA 19-9, CEA, CA 125, CEACAM1, IL-8, PRL, and bHCG), were initially reported for case/control studies [23,26,34,48], the concept that case/control setting are appropriate for initial identification of biomarker candidates may prove valid in highly selective instances. Therefore, ongoing efforts should be aimed at the validation of circulating levels of additional biomarkers shown to be differentially expressed in pancreatic tumors and preneoplastic lesions, such as those summarized in [49], in preclinical serum/plasma samples.

While the high performing panels identified in our previous case/control analysis failed to perform adequately in the current study, the identification of potential alternative panels should provide a sound basis for further development of screening tools. In the training/validation phase of the study, the combination of CA 19-9/CEA performed best, although a statistically significant advantage over CA 19-9 alone was not achieved in the validation set. The inclusion of CEA was somewhat surprising given the observation that levels of CEA were significantly correlated with those of CA 19-9, thus limiting its potential for diagnostic complementation. However, CEA has been previously noted for its relatively high SP but low SN for PDAC [48,50], a trend opposite that of CA 19-9 and it may be that enhancements in SP led to the efficacious performance of this combination. In the unblinded analysis of the entire PLCO set, the combination of CA 19-9, CEA, and Cyfra 21-1 provided the highest level of performance with over 30% of cases correctly identified at 95% SP.

According to a recently described computational model of the clonal evolution of PDAC development, 6.8 years elapse between the development of a malignant clone and metastasis implying that the window for early detection and intervention is wider than initially believed [51,52]. The temporal expression pattern of PDAC biomarkers described here, with changes occurring up to 35 months before diagnosis, indicate the presence of a systemic PDAC signature at pre-metastatic stages. Based on the computational model of PDAC progression, the use of the biomarker panels identified here as screening tools would likely identify some, but not all cases of PDAC prior to the development of metastasis. Although the clinical impact of such a screening strategy remains to be assessed, these findings do suggest that a higher rate of detection of resectable disease, associated with better outcomes, may be attainable in certain high risk groups. Groups at high risk for pancreatic cancer include families identified with Peutz-Jeghers syndrome (relative risk of 132), hereditary pancreatitis (relative risk of 20 to 67), familial atypical multiple mole melanoma (relative risk of 13 to 39), hereditary nonpolyposis colorectal cancer (relative risk of 8.6), familial adenomatous polyposis (relative risk of 4.5), breast and ovarian cancer syndrome (relative risk of 2 to 9), and individuals with multiple first-degree relatives diagnosed with PDAC [53]. Screening among these groups remains feasible with several groups reporting recent efficacy utilizing imaging and CA 19-9/CEA based strategies (reviewed in [54]).

Our analysis provides evidence that several biomarkers demonstrate significant velocity related to time to diagnosis of PDAC. A statistical model based on the velocity of serial CA 125 serum measurements in ovarian cancer patients, termed the Risk of Ovarian Cancer Algorithm (ROCA), has demonstrated efficacy in the early detection of ovarian cancer by offering a significant enhancement in SN in comparison to single measurements of CA 125 [55]. A simulated study also indicated that ROCA may double the SN of CA 125 for early stages of ovarian cancer (S. Skates, personal communication). Two of the biomarkers included in the top performing panel, CA 19-9 and CEA, demonstrated significant velocity related to time to diagnosis, suggesting that serial measurement of these biomarkers may lead to similar
enhancements in panel performance. A study regarding the resectability of presymptomatic pancreatic cancer in diabetic patients indicated that a short window of several years exists when tumors of the pancreas can be visualized by CT and resected [56]. The striking finding in this study is the rapid progression from a normal pancreas to an unresectable tumor. These findings, combined with the molecular model of PDAC progression [52], suggest that specimens collected 1 to 4 years prior to diagnosis would likely lead to the successful identification of candidates for surgical resection. The identification of several biomarkers which selectively demonstrate velocity in sera collected over 1 year prior to diagnosis suggest the presence of biomarker signatures which may be specific for resectable disease. However, these conclusions regarding the efficacy of biomarker velocity in PDAC detection are preliminary and will require further study.

In the study by Palaez-Luna et al. [56] cited above, new onset diabetes was found to be associated with resectable PDAC, however several other studies have reported contradictory findings [57,58]. In the current study, diabetes prevalence (± SEM) differed between cases (14.1±1.10%) and controls (8.0±3.00%) with p = 0.035 (unpaired t test). Also, diabetes rates were significantly different between cases demonstrating an overall survival of less than 6 months (16.7±4.62%), and those with an overall survival of greater than 12 months (0.0±0.00%) with p = 0.005. Although our analysis does not differentiate between new onset and chronic diabetes, these anecdotal findings do support the association between diabetes and PDAC and a particular association with unresectable disease.

Limitations to the current study include the limited extent of diagnostic interval present in our case group. Samples collected beyond 3 years prior to PDAC diagnosis were not available or admissible according to our selection criteria. Such cases would indeed be useful given the extended prediagnostic window suggested by the recent computational modeling of PDAC cited above. Other cohort studies with prospectively collected biospecimens with long-term follow-up could offer the opportunity to address this limitation. The current findings were also limited in that the highest performing biomarker panel was identified through the use of the entire subject cohort as one large training

Figure 3. Biomarker levels in relation to time to diagnosis. Biomarker levels were plotted against the elapsed time interval between blood draw and cancer diagnosis and plots were evaluated by linear regression. Biomarkers demonstrating slopes differing significantly from zero are presented.
doi:10.1371/journal.pone.0094928.g003
References

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, et al. (2012) SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations). National Cancer Institute Bethesda, MD.

2. Michaelsen DS (2004) Epidemiology of pancreatic cancer. Minerva Chir 59: 99–111.

3. Solt TA, Lilligende KD (2000) Surgical palliation of pancreatic cancer. Adv Surg 34: 249–271.

4. Gouette Olles KS, Sierwardena AK (2007) Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Gastroenterol Hepatol 19: 206–270.

5. Chen R, Crigan DA, Pan S, Hawley S, McNichol MW, et al. (2010) Pilot study of blood biomarker candidates for detection of pancreatic cancer. Pancreas 39: 981–988.

6. Koopmann J, Fedako KS, Jain A, Maitra A, Iacobozzino-Daunhaue C, et al. (2004) Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 13: 487–491.

7. Mrzoco B, Lukawczyszcz-Ziac M, Wereszczyzka-Sznitkowska U, Groblewska M, Gryko M, et al. (2009) Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. Pancreas 38: 613–618.

8. Brande R, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, et al. (2011) Serum biomarker panels for the detection of pancreatic cancer. Clinical Cancer Research 17: 805–816.

9. Poruk KE, Forpo MA, Scaife CL, Adler DG, Emerson LL, et al. (2011) Serum osteopontin and tissue inhibitor of metalloproteinase-1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas 40: 193–197.

10. Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, et al. (2008) A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 5: e123.

11. Brand RE, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, et al. (2011) Serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) are derived from, not in response to, pancreatic cancer. J Surg Res 169: 141–149.

12. Michaud DS, Wolpin B, Giovannucci E, Liu S, Cochrane B, et al. (2007) Diagnostic usefulness of serum interleukin-6 (IL-6)- and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis. J Clin Lab Anal 24: 256–261.

13. Chen J, Chen LJ, Xia YL, Zhou RC, Yang RB, et al. (2011) Identification and verification of a potential biomarker for pancreatic ductal adenocarcinoma. J Clin Oncol 29: 1117–1127.

14. Chen J, Wu W, Chen Z, Gao C, Yang R, et al. (2013) Expression and clinical significance of complement C3, complement C4b1 and apolipoprotein E in pancreatic cancer. Oncot Lett 6: 43–48.

15. Mrzoco B, Groblewska M, Gryko M, Bedra B, Szmitkowski M (2010) Diagnostic usefulness of serum interleukin-6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis. J Clin Lab Anal 24: 256–261.

16. Chen J, Chen LJ, Xia YL, Zhou RC, Yang RB, et al. (2013) Identification and verification of a potential biomarker for pancreatic ductal adenocarcinoma. J Clin Oncol 139: 1117–1127.

17. Brande R, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, et al. (2011) Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res 17: 805–816.

18. Syrigos KN, Fysas I, Konstantoulakis MM, Harrington JK, Papadopoulos S, et al. (1998) Beta human chorionic gonadotropin concentrations in serum of patients with pancreatic adenocarcinoma. Gut 42: 80–91.

19. Kleef J, Kostahi NH, Fries H, Fan H, Kore M (2009) Adenosine-mediated transfer of a truncated fibroblast growth factor (FGF) type I receptor blocks FGF2 signaling in multiple pancreatic cancer cell lines. Pancreas 38: 25–30.

20. Xu D, Matsuo Y, Ma J, Koide S, Ochi N, et al. (2010) Cancer cell-derived IL-1alpha promotes HGF secretion by stromal cells and enhances metastatic potential in pancreatic cancer cells. J Surg Oncol 102: 469–477.

21. Poruk KE, Firpo MA, Scaife CL, Adler DG, Emerson LL, et al. (2013) Serum osteopontin and tissue inhibitor of metalloproteinase-1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 19: 2298–2306.

22. Schmiegel WH, Zanchack N, Dhar P, Moore T, Kapchuk HZ (1975) Carcinomobronchial antigen (CEA) in the diagnosis of pancreatic cancer. Cancer 31: 324–327.

23. Poruk KE, Firpo MA, Scaife CL, Adler DG, Emerson LL, et al. (2013) Serum osteopontin and tissue inhibitor of metalloproteinase-1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 19: 2298–2306.

24. Dietel M, Arps H, Klapper R, Muller-Hagen S, Sieck M, et al. (1986) Antigen detection by the monoclonal antibodies CA 19-9 and CA 125 in normal and tumor tissue and patients’ sera. Cancer Res Clin Oncol 111: 237–263.

25. Ona FV, Zanchack N, Dhar P, Moore T, Kapchuk HZ (1975) Carcinomobronchial antigen (CEA) in the diagnosis of pancreatic cancer. Cancer 31: 324–327.

26. Schmiegel WH, Zanchack N, Dhar P, Moore T, Kapchuk HZ (1975) Carcinomobronchial antigen (CEA) in the diagnosis of pancreatic cancer. Cancer 31: 324–327.

27. Schmiegel WH, Zanchack N, Dhar P, Moore T, Kapchuk HZ (1975) Carcinomobronchial antigen (CEA) in the diagnosis of pancreatic cancer. Cancer 31: 324–327.

28. Schmiegel WH, Zanchack N, Dhar P, Moore T, Kapchuk HZ (1975) Carcinomobronchial antigen (CEA) in the diagnosis of pancreatic cancer. Cancer 31: 324–327.

29. Schmiegel WH, Zanchack N, Dhar P, Moore T, Kapchuk HZ (1975) Carcinomobronchial antigen (CEA) in the diagnosis of pancreatic cancer. Cancer 31: 324–327.

30. Schmiegel WH, Zanchack N, Dhar P, Moore T, Kapchuk HZ (1975) Carcinomobronchial antigen (CEA) in the diagnosis of pancreatic cancer. Cancer 31: 324–327.

31. Schmiegel WH, Zanchack N, Dhar P, Moore T, Kapchuk HZ (1975) Carcinomobronchial antigen (CEA) in the diagnosis of pancreatic cancer. Cancer 31: 324–327.

32. Schmiegel WH, Zanchack N, Dhar P, Moore T, Kapchuk HZ (1975) Carcinomobronchial antigen (CEA) in the diagnosis of pancreatic cancer. Cancer 31: 324–327.

33. Schmiegel WH, Zanchack N, Dhar P, Moore T, Kapchuk HZ (1975) Carcinomobronchial antigen (CEA) in the diagnosis of pancreatic cancer. Cancer 31: 324–327.

34. Schmiegel WH, Zanchack N, Dhar P, Moore T, Kapchuk HZ (1975) Carcinomobronchial antigen (CEA) in the diagnosis of pancreatic cancer. Cancer 31: 324–327.

35. Schmiegel WH, Zanchack N, Dhar P, Moore T, Kapchuk HZ (1975) Carcinomobronchial antigen (CEA) in the diagnosis of pancreatic cancer. Cancer 31: 324–327.

36. Schmiegel WH, Zanchack N, Dhar P, Moore T, Kapchuk HZ (1975) Carcinomobronchial antigen (CEA) in the diagnosis of pancreatic cancer. Cancer 31: 324–327.

37. Schmiegel WH, Zanchack N, Dhar P, Moore T, Kapchuk HZ (1975) Carcinomobronchial antigen (CEA) in the diagnosis of pancreatic cancer. Cancer 31: 324–327.

38. Schmiegel WH, Zanchack N, Dhar P, Moore T, Kapchuk HZ (1975) Carcinomobronchial antigen (CEA) in the diagnosis of pancreatic cancer. Cancer 31: 324–327.

39. Schmiegel WH, Zanchack N, Dhar P, Moore T, Kapchuk HZ (1975) Carcinomobronchial antigen (CEA) in the diagnosis of pancreatic cancer. Cancer 31: 324–327.

40. Schmiegel WH, Zanchack N, Dhar P, Moore T, Kapchuk HZ (1975) Carcinomobronchial antigen (CEA) in the diagnosis of pancreatic cancer. Cancer 31: 324–327.
44. Kaur S, Chakraborty S, Baine MJ, Mallick K, Smith LM, et al. (2013) Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. PLoS One 8: e55171.

45. Ben QW, Jin XL, Liu J, Cai X, Yuan F, et al. (2011) Periostin, a matrix specific protein, is associated with proliferation and invasion of pancreatic cancer. Oncol Rep 25: 709–716.

46. Park HD, Kang ES, Kim JW, Lee KT, Lee KH, et al. (2012) Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. Proteomics 12: 3590–3597.

47. Ballehaninna UK, Chamberlain RS (2013) Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. Tumour Biol.

48. Duraker N, Hot S, Polat Y, Hobek A, Gender N, et al. (2007) CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol 95: 142–147.

49. Harsha HC, Kandasamy K, Ranganathan P, Rani S, Ramabadran S, et al. (2009) A compendium of potential biomarkers of pancreatic cancer. PLoS Med 6: e1000046.

50. Ehmann M, Felix K, Hartmann D, Schnozer M, Nees M, et al. (2007) Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 34: 205–214.

51. Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, et al. (2010) Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci U S A 107: 18545–18550.

52. Yachida S, Jones S, Bozic I, Antal T, Leary R, et al. (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114–1117.

53. Shin EJ, Canto MI (2012) Pancreatic cancer screening. Gastroenterol North Am 41: 143–157.

54. Gonda TA, Lucas A, Safi MW (2011) Screening and detection of pancreatic cancer. Highlights from the “2011 ASCO Annual Meeting”. Chicago, IL, USA; June 3–7, 2011. JOP 12: 322–324.

55. Skates SJ (2012) Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials. Int J Gynecol Cancer 22 Suppl 1: S24–26.

56. Pelaez-Luna M, Takahashi N, Fletcher JG, Chari ST (2007) Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol 102: 2157–2163.

57. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, et al. (2005) Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 129: 504–511.

58. Damiano J, Bordier I, Le Berre JP, Margery J, Dupuy O, et al. (2004) Should pancreas imaging be recommended in patients over 50 years when diabetes is discovered because of acute symptoms? Diabetes Metab 30: 205–207.

59. Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, et al. (2004) Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 10: 2386–2392.

60. Tezel E, Kaseye Y, Takeda S, Oshima K, Nakao A (2001) Expression of neural cell adhesion molecule in pancreatic cancer. Pancreas 22: 122–125.